Neola Medical (NEOLA) Q3 2024 earnings summary

Executive summary

• Advanced to clinical validation phase, preparing for pivotal U.S. clinical study on preterm infants in 2025 and targeting FDA approval.

• Completed Human Factors Validation Study in Boston with U.S. neonatal nurses, supporting FDA application.

• Achieved key milestones: CB certificate, U.S. and European patent grants, and won Stanford Pediatric Device Competition.

• Strengthened U.S. presence with new board member and established Neola Medical Inc. in Palo Alto.

• Focused on U.S. market launch, targeting leading children's hospitals and building strategic partnerships.

Financial highlights

• Operating expenses increased by 1.8 million SEK year-to-date, mainly due to human factor study and team expansion.

• Q3 2024 operating result: SEK -2,476k; nine months: SEK -8,055k; EPS: -0.11 SEK.

• Cash and cash equivalents at period end: SEK 24,161k; equity ratio 93%; no interest-bearing debt.

• Maintained strong cost control despite increased development activity; burn rate expected to rise with upcoming studies.

• SEK 19,931k raised from new share issues in early 2024, boosting cash position.

Outlook and guidance

• Pivotal U.S. clinical study scheduled for 2025, with pilot study in Sweden as preparation.

• FDA and CE mark submissions targeted for late 2025 and mid-2026, with approvals expected in 2026/2027.

• U.S. market launch expected in 2026, with focus on building pilot cases at select hospitals.

• Revenue growth expected to be driven by disposable probes post-launch.

• Burn rate expected to increase as clinical validation accelerates and commercial preparations begin.